TY - JOUR
T1 - Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP
T2 - a single-institute retrospective study
AU - Yamasaki, Satoshi
AU - Matsushima, Takumi
AU - Minami, Mariko
AU - Kadowaki, Masanori
AU - Takase, Ken
AU - Iwasaki, Hiromi
N1 - Funding Information:
We thank the patients and clinical staff for their participation in the study. We also acknowledge the Clinical Research Institute, Kyushu Medical Hospital for editorial support. The article processing charges were funded by the authors. We thank Joe Barber Jr, PhD, and H. Nikki March, PhD, from Edanz ( https://www.jp.edanz.com/ac ) for editing drafts of this manuscript.
Funding Information:
No funding or sponsorship was received for this study or for the publication of this article. The article processing charges were funded by the authors.
Publisher Copyright:
© 2021, European Geriatric Medicine Society.
PY - 2021
Y1 - 2021
N2 - Purpose: Comprehensive geriatric assessment (CGA) has been used to help identify elderly patients with diffuse large B-cell lymphoma (DLBCL) who were suitable for rituximab combined with CHOP therapy (cyclophosphamide, Adriamycin, vincristine, and prednisolone), but there are few reports of CGA for elderly patients with DLBCL who received R-mini-CHOP. Methods: We retrospectively analyzed the risk factors for outcomes among 142 patients aged 80 years and older (≤ 85 years, n = 102; > 85 years, n = 40) with DLBCL who received R-mini-CHOP at 4-week intervals at our institute between 2008 and 2019. We performed a comparison between CGA and treatment outcomes. Results: There were significant differences in progression-free survival between patients with international prognostic index (IPI) scores of > 3 and ≤ 3 at diagnosis and in overall survival between patients with instrumental activities of daily living (IADL) scores of ≥ 5 and IADL < 5 before the initial treatment and patients aged ≤ 85 years and > 85 years. Conclusion: Strategies that carefully select elderly patients aged 80 years and older with DLBCL using CGA may help to identify individuals suitable for novel therapies.
AB - Purpose: Comprehensive geriatric assessment (CGA) has been used to help identify elderly patients with diffuse large B-cell lymphoma (DLBCL) who were suitable for rituximab combined with CHOP therapy (cyclophosphamide, Adriamycin, vincristine, and prednisolone), but there are few reports of CGA for elderly patients with DLBCL who received R-mini-CHOP. Methods: We retrospectively analyzed the risk factors for outcomes among 142 patients aged 80 years and older (≤ 85 years, n = 102; > 85 years, n = 40) with DLBCL who received R-mini-CHOP at 4-week intervals at our institute between 2008 and 2019. We performed a comparison between CGA and treatment outcomes. Results: There were significant differences in progression-free survival between patients with international prognostic index (IPI) scores of > 3 and ≤ 3 at diagnosis and in overall survival between patients with instrumental activities of daily living (IADL) scores of ≥ 5 and IADL < 5 before the initial treatment and patients aged ≤ 85 years and > 85 years. Conclusion: Strategies that carefully select elderly patients aged 80 years and older with DLBCL using CGA may help to identify individuals suitable for novel therapies.
UR - http://www.scopus.com/inward/record.url?scp=85109902768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109902768&partnerID=8YFLogxK
U2 - 10.1007/s41999-021-00539-8
DO - 10.1007/s41999-021-00539-8
M3 - Article
AN - SCOPUS:85109902768
JO - European Geriatric Medicine
JF - European Geriatric Medicine
SN - 1878-7649
ER -